Thus, cancer treatments provide clues to a possible method for the treatment of AD and nilotinib; a c-Abl inhibitor seems to be an interesting approach in the treatment of neurodegenerative diseases such as PD and perhaps AD [11,12,21,33,34]. Here, ABL1 is linked to Parkinson disease.